Skip to main content
. Author manuscript; available in PMC: 2015 Oct 14.
Published in final edited form as: J Geriatr Oncol. 2015 Jan 19;6(3):211–218. doi: 10.1016/j.jgo.2015.01.003

Table 1.

Age-standardized baseline characteristics of elderly US veterans diagnosed with DLBCL 1998-2008, stratified by treatment group (N=476)

AT Non-AT NT
Demographic and Clinical Characteristics n=198 n=87 n=191 p-value
Age at Diagnosis (mean years) 83.1 83.6 83.8 0.048d
Sex (Male %) 99 95.4 97.9 0.196b
Race (%) 0.322b
    White 94.4 89.7 92.2
    Black 3.5 5.8 5.2
    Others 2 4.6 2.6
Stage (%) 0.598c
    Stage I/II 43.9 37.9 41.9
    Stage III/IV 56.1 62.1 56
    Unknown 0 0 2.1
LDH (%) 0.23c
    Elevated 50 49.4 32.5
    Not Elevated 41.9 43.7 18.3
    Unknown 8.1 6.9 49.2
ECOG Performance status (%) <.001c
    0-1 52 37.9 10
    2-4 46.5 60.9 86.4
    Unknown 1.5 1.2 3.7
Age adjusted IPI (%)a 0.145b
        0 16.2 8.1
        1 27.8 31
        2 31.8 26.4
        3 14.7 27.6
        Unknown 9.6 6.9
Co-morbidity (mean Charlson score) 1.8 2.3 2.5 <0.001d
B-symptom( %) 0.037b
        Yes 42.4 55.2 50.8
        No 55.1 43.7 41.4
        Unknown 2.5 1.2 7.9
Myeloid growth factor use (%)a 78.8 45.2 <.001b
Rituximab use (%)a 80.3 77 0.501b
Year of diagnosis (Median) 2005 2005 2004 0.114e
Treatment Regimens a
        CHOP/R-CHOP 190 -
        CNOP/R-CNOP 5 -
        CVP/R-CVP - 53
        R-EPOCH 1 -
        Rituximab - 21
        Other 2 13

Footnote:

a

Comparison between doxorubicin and non-doxorubicin groups only

b

Chi-Square or Fisher's exact test

c

Row mean score test

d

One way ANOVA

e

Kruskal-Wallis Test

Abbreviations used: DLBCL=Diffuse Large B-cell Lymphoma; N=number; AT= Anthracycline based therapy; non-AT= Non-anthracycline based therapy; NT= No treatment; LDH= Lactate dehydrogenase; ECOG=Eastern Cooperative Oncology Group; IPI=International Prognostic Index; CHOP/R-CHOP=Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone, Rituximab; CNOP/R-CNOP=Cyclophosphamide, Novantrone, Oncovin, Prednisone, Rituximab; CVP/R-CVP=Cyclophosphamide, Vincristine, Prednisone, Rituximab; R-EPOCH=Rituximab, Etoposide, Prednisone, Oncovin, Cyclophosphamide, Hydroxydaunorubicin.